Metabolomic Profiling in LRRK2-Related Parkinson's Disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Mutations in LRRK2 gene represent the most common known genetic cause of Parkinson's disease (PD). METHODOLOGY/PRINCIPAL FINDINGS: We used metabolomic profiling to identify biomarkers that are associated with idiopathic and LRRK2 PD. We compared plasma metabolomic profiles of patients with PD due to the G2019S LRRK2 mutation, to asymptomatic family members of these patients either with or without G2019S LRRK2 mutations, and to patients with idiopathic PD, as well as non-related control subjects. We found that metabolomic profiles of both idiopathic PD and LRRK2 PD subjects were clearly separated from controls. LRRK2 PD patients had metabolomic profiles distinguishable from those with idiopathic PD, and the profiles could predict whether the PD was secondary to LRRK2 mutations or idiopathic. Metabolomic profiles of LRRK2 PD patients were well separated from their family members, but there was a slight overlap between family members with and without LRRK2 mutations. Both LRRK2 and idiopathic PD patients showed significantly reduced uric acid levels. We also found a significant decrease in levels of hypoxanthine and in the ratios of major metabolites of the purine pathway in plasma of PD patients. CONCLUSIONS/SIGNIFICANCE: These findings show that LRRK2 patients with the G2019S mutation have unique metabolomic profiles that distinguish them from patients with idiopathic PD. Furthermore, asymptomatic LRRK2 carriers can be separated from gene negative family members, which raises the possibility that metabolomic profiles could be useful in predicting which LRRK2 carriers will eventually develop PD. The results also suggest that there are aberrations in the purine pathway in PD which may occur upstream from uric acid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Assessment of PLSDA Cross Validation
Westerhuis, J. A., Hoefsloot, H. C. J., Smit, S., Vis, D. J., Smilde, A. K., van Velzen, E. J. J., van Duijnhoven, J. P. M., & van Dorsten, F. A. (2008) · Metabolomics · doi:10.1007/s11306-007-0099-6 · Cited by 1,471
Thomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Self-citationTokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · cited 1×
“Decreased levels of a-synuclein in CSF, and an elevated level of the oligomeric protein in plasma have been reported [12,13], but neither is recognized as a diagnostic marker.”
Background
Cited by
Identification of novel biomarkers for Parkinson's disease by metabolomic technologies
Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P., & Hattori, N. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309676 · Cited by 282
Metabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases
Jové, M., Portero-Otín, M., Naudí, A., Ferrer, I., & Pamplona, R. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000091 · Cited by 195
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivo
Mortiboys, H., Furmston, R., Bronstad, G., Aasly, J., Elliott, C., & Bandmann, O. (2015) · Neurology · doi:10.1212/wnl.0000000000001905 · Cited by 131
“Future studies have to determine whether there is a possible link between the mitochondrial dysfunction in NM-LRRK2 observed in this study and previously reported imaging or metabolomic profiling abnormalities in NM-LRRK2.(21,22) In vivo as well as in vitro energy demand may contribute to the mechanisms by which LRRK2…”
Self-citationCerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile
Kaddurah-Daouk, R., Yuan, P., Boyle, S. H., Matson, W., Wang, Z., Zeng, Z. B., Zhu, H., Dougherty, G. G., Yao, J. K., Chen, G., et al. (2012) · Scientific Reports · doi:10.1038/srep00667 · Cited by 76
Self-citationMetabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease
Yakhine-Diop, S. M. S., Morales-García, J. A., Niso-Santano, M., González-Polo, R. A., Uribe-Carretero, E., Martinez-Chacon, G., Durand, S., Maiuri, M. C., Aiastui, A., Zulaica, M., et al. (2020) · Aging · doi:10.18632/aging.103992 · Cited by 50
Metadata
- Authors
- Johansen, K. K., Wang, L., Aasly, J. O., White, L. R., Matson, W. R., Henchcliffe, C., Beal, M. F., & Bogdanov, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-10-22
- Volume
- 4
- Issue
- 10
- Pages
- e7551
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2027692436
- Cited by
- 155
- References
- 4
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolomic Profiling in LRRK2-Related Parkinson's Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0007551
- The paper
- Johansen, K. K., Wang, L., Aasly, J. O., White, L. R., Matson, W. R., Henchcliffe, C., Beal, M. F., & Bogdanov, M. (2009). Metabolomic Profiling in LRRK2-Related Parkinson's Disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0007551
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.